New hope for tough lung cancer: experimental drug faces off against standard care
NCT ID NCT07365241
First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or one of three usual drugs (topotecan, lurbinectedin, or amrubicin) to see which works better and is safer. The goal is to shrink tumors and help people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.